NCT03965234 is a Phase 1, PHASE2 clinical trial of Cisplatin in Metastatic Bone Sarcoma, sponsored by Roswell Park Cancer Institute.

Who is sponsoring NCT03965234?

NCT03965234 is sponsored by Roswell Park Cancer Institute.

What drugs are being tested in NCT03965234?

Interventions in NCT03965234: Cisplatin, Isolated Chemotherapeutic Lung Perfusion, Metastasectomy.

What condition does NCT03965234 study?

NCT03965234 studies Metastatic Bone Sarcoma, Metastatic Malignant Neoplasm in the Lung, Metastatic Soft Tissue Sarcoma, Metastatic Unresectable Sarcoma, Resectable Sarcoma, Colorectal Cancer.

Is NCT03965234 still recruiting?

NCT03965234 is currently recruiting now. Last updated 17 March 2026.

Last reviewed 2026-03-17 · How we verify

NCT03965234

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Recruiting now Phase 1, PHASE2 Last updated 17 March 2026

What this trial tests

Phase 1, PHASE2 trial testing Cisplatin in Metastatic Bone Sarcoma in 99 participants. Currently enrolling.

Timeline

16 July 2020

Primary endpoint
25 May 2029

25 May 2030

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	99
Start date	16 July 2020
Primary completion	25 May 2029
Estimated completion	25 May 2030
Sites	1 location across United States

Drugs / interventions tested

Cisplatin (cisplatin) — full drug profile →
Isolated Chemotherapeutic Lung Perfusion
Metastasectomy

Conditions studied

Metastatic Bone Sarcoma — all drugs for Metastatic Bone Sarcoma →
Metastatic Malignant Neoplasm in the Lung — all drugs for Metastatic Malignant Neoplasm in the Lung →
Metastatic Soft Tissue Sarcoma — all drugs for Metastatic Soft Tissue Sarcoma →
Metastatic Unresectable Sarcoma — all drugs for Metastatic Unresectable Sarcoma →

Sponsor

Roswell Park Cancer Institute

Who can join

18 and older, any sex, with Metastatic Bone Sarcoma or Metastatic Malignant Neoplasm in the Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pulmonary suffusion may also be useful in avoiding later use of drugs by vein that demonstrate no effect on tumors when delivered locally.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pulmonary Suffusion Refinements for Primary and Secondary Malignancies: Preliminary Analyses of Phase I Safety and Drug Delivery Data.
Demmy T, Abdelhady S, Tomaszewski G, Petroziello M, et al · · 2025 · PMID 40940977 · DOI 10.3390/cancers17172880

Verify or expand the search:

Other trials of Cisplatin

Trials testing the same drug.

NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07195734 — Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · Phase 2 · recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03965234 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 17 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03965234.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing